Acute mixed-lineage leukemia treated with desensitization therapy prior to HLA-haploidentical transplantation with high donor-specific antibodies
Int J Hematol. 2024 Apr 27. doi: 10.1007/s12185-024-03775-3. Online ahead of print.ABSTRACTA 43-year-old woman was referred to our department for hematopoietic stem cell transplantation for acute myeloid leukemia, as she failed to achieve remission following induction therapy. Umbilical cord blood transplantation was initially planned; however, multiple anti-human leukocyte antigen (HLA) antibodies with a mean fluorescence intensity of over 10,000 were detected, and optimal umbilical cord blood could not be obtained. The plan was then switched to peripheral blood stem cell transplantation (PBSCT) from the patient's son, wh...
Source: International Journal of Hematology - April 27, 2024 Category: Hematology Authors: Kengo Katsuki Takayoshi Tachibana Akihiko Izumi Kumryo Kim Taisei Suzuki Masatsugu Tanaka Hideaki Nakajima Source Type: research
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Curr Oncol. 2024 Apr 3;31(4):1971-1993. doi: 10.3390/curroncol31040148.ABSTRACTMyelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutati...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Daniel Karel Claire Valburg Navitha Woddor Victor E Nava Anita Aggarwal Source Type: research
A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related
CONCLUSION: MPN-BP and AML-MR harbor similar somatic mutations and clinical outcomes, suggesting a unified clinical disease entity.PMID:38665121 | DOI:10.1111/ijlh.14280 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - April 26, 2024 Category: Hematology Authors: Dong Chen Julia Geyer Adam Bagg Robert Hasserjian Olga K Weinberg Source Type: research
RNF138 inhibits transcription factor C/EBP α protein turnover leading to differentiation arrest in AML
Biochem J. 2024 Apr 26:BCJ20240027. doi: 10.1042/BCJ20240027. Online ahead of print.ABSTRACTE3 ubiquitin ligase, ring finger protein 138 (RNF138) is involved in several biological processes; however, its role in myeloid differentiation or tumorigenesis remains unclear. RNAseq data from TNMplot showed that RNF138 mRNA levels are highly elevated in Acute Myeloid Leukemia (AML) bone marrow samples as compared to bone marrow of normal volunteers. Here, we show that RNF138 serves as an E3 ligase for the tumor suppressor CCAAT/enhancer binding protein (C/EBPα) and promotes its degradation leading to myeloid differentiation arre...
Source: The Biochemical Journal - April 26, 2024 Category: Biochemistry Authors: Anil Kumar Singh Vishal Upadhyay Arppita Sethi Sangita Chaowdhury Shivkant Mishra Shailednra Prasad Verma Madan Lal Brahma Bhatt Arun Kumar Trivedi Source Type: research
FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Curr Issues Mol Biol. 2024 Mar 29;46(4):2946-2960. doi: 10.3390/cimb46040184.ABSTRACTTargeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML). The FLT3 and IRAK4 inhibitor emavusertib (CA4948), the MCL1 inhibitor S63845, the BCL2 inhibitor venetoclax, and the HSP90 inhibitor PU-H71 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells in vitro. AML cells represented all major morphologic and molecular subtypes, includi...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Katja Seipel Harpreet Mandhair Ulrike Bacher Thomas Pabst Source Type: research
FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Curr Issues Mol Biol. 2024 Mar 29;46(4):2946-2960. doi: 10.3390/cimb46040184.ABSTRACTTargeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML). The FLT3 and IRAK4 inhibitor emavusertib (CA4948), the MCL1 inhibitor S63845, the BCL2 inhibitor venetoclax, and the HSP90 inhibitor PU-H71 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells in vitro. AML cells represented all major morphologic and molecular subtypes, includi...
Source: Mol Biol Cell - April 26, 2024 Category: Molecular Biology Authors: Katja Seipel Harpreet Mandhair Ulrike Bacher Thomas Pabst Source Type: research
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Curr Oncol. 2024 Apr 3;31(4):1971-1993. doi: 10.3390/curroncol31040148.ABSTRACTMyelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutati...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Daniel Karel Claire Valburg Navitha Woddor Victor E Nava Anita Aggarwal Source Type: research
Investigating the safety and feasibility of osteopathic manipulative medicine in hospitalized children and adolescent young adults with cancer
CONCLUSIONS: Hospitalized children and AYAs with cancer received OMT safely with decreased pain in their reported somatic dysfunction(s). These findings support further investigation into the safety, feasibility, and efficacy of implementing OMT in the pediatric oncology inpatient setting and to a broader inpatient pediatric oncology population.PMID:38669608 | DOI:10.1515/jom-2024-0013 (Source: Pain Physician)
Source: Pain Physician - April 26, 2024 Category: Anesthesiology Authors: Jennifer A Belsky Amber M Brown Source Type: research
A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related
CONCLUSION: MPN-BP and AML-MR harbor similar somatic mutations and clinical outcomes, suggesting a unified clinical disease entity.PMID:38665121 | DOI:10.1111/ijlh.14280 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - April 26, 2024 Category: Hematology Authors: Dong Chen Julia Geyer Adam Bagg Robert Hasserjian Olga K Weinberg Source Type: research
CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment
Int J Hematol. 2024 Apr 26. doi: 10.1007/s12185-024-03773-5. Online ahead of print.ABSTRACTMutations in CCAAT enhancer binding protein α (CEBPA) occur in approximately 10% of patients with de novo acute myeloid leukemia (AML). Emerging evidence supports that in-frame mutations in the basic leucine zipper domain of CEBPA (CEBPAbZIP-inf) confer a survival benefit, and CEBPAbZIP-inf replaced CEBPA double mutations (CEBPAdm) as a unique entity in the 2022 World Health Organization (WHO-2022) classification and International Consensus Classification (ICC). However, challenges remain in daily clinical practice since more than 3...
Source: International Journal of Hematology - April 26, 2024 Category: Hematology Authors: Feng-Ming Tien Hsin-An Hou Source Type: research
RNF138 inhibits transcription factor C/EBP α protein turnover leading to differentiation arrest in AML
Biochem J. 2024 Apr 26:BCJ20240027. doi: 10.1042/BCJ20240027. Online ahead of print.ABSTRACTE3 ubiquitin ligase, ring finger protein 138 (RNF138) is involved in several biological processes; however, its role in myeloid differentiation or tumorigenesis remains unclear. RNAseq data from TNMplot showed that RNF138 mRNA levels are highly elevated in Acute Myeloid Leukemia (AML) bone marrow samples as compared to bone marrow of normal volunteers. Here, we show that RNF138 serves as an E3 ligase for the tumor suppressor CCAAT/enhancer binding protein (C/EBPα) and promotes its degradation leading to myeloid differentiation arre...
Source: The Biochemical Journal - April 26, 2024 Category: Biochemistry Authors: Anil Kumar Singh Vishal Upadhyay Arppita Sethi Sangita Chaowdhury Shivkant Mishra Shailednra Prasad Verma Madan Lal Brahma Bhatt Arun Kumar Trivedi Source Type: research
FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Curr Issues Mol Biol. 2024 Mar 29;46(4):2946-2960. doi: 10.3390/cimb46040184.ABSTRACTTargeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML). The FLT3 and IRAK4 inhibitor emavusertib (CA4948), the MCL1 inhibitor S63845, the BCL2 inhibitor venetoclax, and the HSP90 inhibitor PU-H71 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells in vitro. AML cells represented all major morphologic and molecular subtypes, includi...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Katja Seipel Harpreet Mandhair Ulrike Bacher Thomas Pabst Source Type: research
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Curr Oncol. 2024 Apr 3;31(4):1971-1993. doi: 10.3390/curroncol31040148.ABSTRACTMyelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutati...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Daniel Karel Claire Valburg Navitha Woddor Victor E Nava Anita Aggarwal Source Type: research
A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related
CONCLUSION: MPN-BP and AML-MR harbor similar somatic mutations and clinical outcomes, suggesting a unified clinical disease entity.PMID:38665121 | DOI:10.1111/ijlh.14280 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - April 26, 2024 Category: Hematology Authors: Dong Chen Julia Geyer Adam Bagg Robert Hasserjian Olga K Weinberg Source Type: research
RNF138 inhibits transcription factor C/EBP α protein turnover leading to differentiation arrest in AML
Biochem J. 2024 Apr 26:BCJ20240027. doi: 10.1042/BCJ20240027. Online ahead of print.ABSTRACTE3 ubiquitin ligase, ring finger protein 138 (RNF138) is involved in several biological processes; however, its role in myeloid differentiation or tumorigenesis remains unclear. RNAseq data from TNMplot showed that RNF138 mRNA levels are highly elevated in Acute Myeloid Leukemia (AML) bone marrow samples as compared to bone marrow of normal volunteers. Here, we show that RNF138 serves as an E3 ligase for the tumor suppressor CCAAT/enhancer binding protein (C/EBPα) and promotes its degradation leading to myeloid differentiation arre...
Source: The Biochemical Journal - April 26, 2024 Category: Biochemistry Authors: Anil Kumar Singh Vishal Upadhyay Arppita Sethi Sangita Chaowdhury Shivkant Mishra Shailednra Prasad Verma Madan Lal Brahma Bhatt Arun Kumar Trivedi Source Type: research
